Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in
subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in
3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each
cycle is 28 days.
Phase:
Phase 2
Details
Lead Sponsor:
International Myeloma Foundation
Collaborators:
Amgen Celgene Celgene Inc Janssen Scientific Affairs, LLC Trevie, Inc.